Iloprost for Additional Anticoagulation in Continuous Renal Replacement Therapy—A Pilot Study

Autor:	Christian Lehmann, Jiirgen Birnbaum, René Saalmann, Mona S. Grund, Stanislao Morgera, Wolfgang J. Kox, Tania Schink, Ortrud Vargas Hein, Claudia Spies, Edda Klotz, Sabine Ziemer
Rok vydání:	2007
Předmět:	Male Nephrology medicine.medical_specialty medicine.drug_class medicine.medical_treatment Pilot Projects Critical Care and Intensive Care Medicine law.invention law Internal medicine Hemofiltration medicine Humans Iloprost Prospective Studies Renal replacement therapy Infusions Intravenous Blood Coagulation Aged Aged 80 and over Analysis of Variance medicine.diagnostic_test Heparin Platelet Count business.industry Anticoagulant Anticoagulants General Medicine Acute Kidney Injury Middle Aged Platelet Activation Intensive care unit Treatment Outcome Anesthesia Drug Therapy Combination Female Partial Thromboplastin Time business Biomarkers Platelet Aggregation Inhibitors Partial thromboplastin time medicine.drug
Zdroj:	Renal Failure. 29:271-277
ISSN:	1525-6049 0886-022X
DOI:	10.1080/08860220601166222
Popis:	The aim of this pilot study was to compare the effect of heparin anticoagulation with and without iloprost administration during continuous renal replacement therapy (CRRT) in critically ill patients.In a prospective, randomized, controlled pilot study at an intensive care unit at a university hospital, 20 patients requiring CRRT were investigated. Patients were allocated into two groups: group 1, the heparin group; and group 2, the heparin plus 1 ng/kg/min iloprost. In both groups, activated partial thromboplastin time (aPTT) was adjusted to 40-50 sec. Observation time was a maximum of 7 days.Median filter run time was significantly prolonged by iloprost administration to a median of 14 h (13-26 h) compared to 10 h (4-12 h) in the heparin group (p = 0.004). A decrease in platelet count was attenuated by iloprost administration (p = 0.012). There were no bleeding complications in either group. Hemofiltration efficiency did not differ significantly between the groups.Additional administration of iloprost prolonged the filter run time of continuous veno-venous hemofiltration (CVVH) in this setting and attenuated the fall in platelet count during CRRT.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e91539fa497187f59fbb620c01b0c34 https://doi.org/10.1080/08860220601166222 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.